logo
Hawaii eighth in health foundation's ranking

Hawaii eighth in health foundation's ranking

Yahoo30-01-2025

Hawaii ranked among the top 10 states for high health rankings, according to a recently released report by the United Health Foundation.
Hawaii ranked eighth-best among states in key health measures, according to America's Health Rankings 2024 Annual Report—a drop from sixth place in 2023.
While the state got the top ranking for its low rates of adults avoiding care due to cost, it ranked in the bottom half for other factors, including No. 34 for the number of primary care providers and No. 36 in the economic hardship index.
'For many key indicators of public health, the data show that Hawaii performs exceptionally well, ' said Dr. Kenneth Fink, Hawaii Department of Health director, in a news release. 'However, in certain areas—primarily economic factors and certain personal behaviors—there are opportunities for improvement.'
The report is the longest-running annual assessment of the nation's health on a state-by-state basis, according to the foundation. The 2024 report ranked states based on 88 measures spanning five categories of health and well-being.
Hawaii ranked No. 1 for health outcomes, due in part to recording the lowest rates in the nation for frequent mental distress reported among adults (13 %) and racial disparities in premature death ; the second-lowest rate of adult obesity (26 %); and the third-lowest rate of adults with multiple chronic conditions (7.7 %).
Don 't miss out on what 's happening !
Stay in touch with breaking news, as it happens, conveniently in your email inbox. It 's FREE !
Email 28141 Sign Up By clicking to sign up, you agree to Star-Advertiser 's and Google 's and. This form is protected by reCAPTCHA.
Cases of frequent mental distress among adults, however, jumped 54 % from 2014 to 2023.
For clinical care, Hawaii ranked No. 7 due in part to recording the lowest rates in the nation for avoided care due to cost (6.7 %) and No. 2 for the second-lowest percentage of population uninsured (3.2 %).
Hawaii ranked lower for categories that looked at social and economic factors affecting public health.
The state ranked 36th on a scale of 1 to 100 for the Economic Hardship Index, which factors in crowded housing, per capita income, and poverty and unemployment rates.
Socially, Hawaii also ranked low for voter participation, at 34th, and volunteerism, at 45th.
Hawaii ranked high for number of dental care providers, at No. 4, but in the bottom half for number of mental health providers, at No. 28, and number of primary care providers, at No. 34.
The state offered a mixed bag in the category of physical environment—a top ranking for low rates of air pollution and drinking water violations, on one hand, but a bottom ranking for water fluoridation, on the other hand.
Hawaii does not add fluoride to its public drinking water system to help battle cavities and tooth decay. The Honolulu City Council in 2004 voted to from being added to Oahu's public water supply.
The state's legislative efforts to change the ban have so far been.
Hawaii residents also ranked No. 44 for percentage of adults that use e-cigarettes (10 %) and drink excessively (20 %)—and at the bottom, No. 50, for percentage of adults with insufficient sleep (45.6 %).
The report also found that drug deaths increased 74 %, from 11.3 to 19.7 deaths per 100, 000 people between 2013 and 2022.
In overall ranking, New Hampshire ranked first, Vermont second, and Massachusetts third. Louisiana was 50th, at the bottom of the overall ranking.
Monitoring state's health Where Hawaii ranked :—Overall rank : 8th—Health outcomes : 1st—Clinical care : 7th—Social & Economic Factors : 14th—Behaviors : 17th—Physical environment : 27th A closer look—Premature death racial disparity : 1st—Obesity among adults : 2nd—Percent of population uninsured : 2nd—Multiple chronic conditions among adults : 3rd—Dental visits among adults : 3rd—Premature deaths : 6th—4th grade reading proficiency : 8th—Childhood immunizations : 17th—Fruit and vegetable consumption : 19th—Mental health providers (per 100, 000 ): 28th—Primary care providers (per 100, 000 ): 34th—Voter participation : 34th—Economic hardship index : 36th—E-cigarette use among adults : 44th—Excessive drinking among adults : 44th—Volunteerism : 45th—Severe housing problems : 50th—Sleep health : 50th—Water fluoridation : 50th Key findings—Drug deaths increased 74 % (from 2013 to 2022 )—Frequent mental distress increased 54 % (from 2014 to 2023 )—Teen births dropped 53 % (from 2013 to 2022 )—Uninsured declined 40 % (from 2014 to 2023 )
Source : America's Health Rankings 2024 Annual Report

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Jayson Tatum gives first update on Achilles tear rehab
Jayson Tatum gives first update on Achilles tear rehab

Yahoo

time19 hours ago

  • Yahoo

Jayson Tatum gives first update on Achilles tear rehab

Jayson Tatum has a grueling road ahead after undergoing surgery for an Achilles tear last month. However, the Celtics star gave a brief optimistic update on his recovery in a post on X Saturday. 'Day 25…days starting to get a little easier,' Tatum wrote in a X post. Advertisement Tatum underwent surgery for his right Achilles tear on May 13 after suffering the injury in Game 4 of the Eastern Conference Semifinals against the Knicks. His only other public comment since the injury has been an Instagram post on May 14 thanking everyone for their support following the injury. Tatum underwent surgery on his torn Achilles less than 24 hours after suffering the Achilles tear. However, the fast turnaround with the surgery may end up proving to be beneficial according to Brad Stevens. 'Super hard for Jayson, more than anybody,' Stevens said last month about the aftermath of the injury. 'As has been well documented, he loves to play, and I think even missing two games has been grueling for him. So we know that there is a long road ahead and that there's going to be several steps that he'll have to take before he ultimately gets back out on the court, but the positive was we were 15 minutes away from Dr. O'Malley, who is a terrific surgeon, who has done a number of these. '[Team doctor] Dr. Schena was on the phone with him before we left the building on Monday night, and he was out of the MRI and consultation and done with surgery by the time we had an injury report the next day, because there was real benefit to doing it early. So as tough as that injury is and as tough as that was that night, just an amazing set of circumstances, and an amazing thank you from our organization to Dr. O'Malley, the nurses at HSS and everybody there, the hotel that we were staying in and the accommodations they made Jayson feel comfortable in. I thought it was about as good of a transition in about as bleak of a feeling as you could have.' Advertisement In a follow up interview with Chris Forsberg of NBC Sports Boston last month, Stevens elaborated on the potential impact of Tatum's quick surgery on his recovery. 'Blood supply and different swelling benefits early on in those first 72 hours was the timeframe we were talking about,' Stevens said. 'We were fortunate to be there at HSS. I thought they did a great job. Our team doc did a great job of helping organize it. We were there with Brandy and Jayson and Jeff Wexler, his agent and everyone was quick to make that call. I think there's real benefit to that.' The Celtics have not commented on a timetable for Tatum's recovery but Tatum's father indicated to Marc Spears of ESPN that the Celtics All-Star expects to return in 8-9 months. Players who have returned from an Achilles tear in the NBA in the past year have need anywhere from 8-18 months for their recovery before returning to the floor. The Celtics will try to retool their roster around Tatum this summer in the aftermath of a disappointing second round exit this past season. Advertisement 'I mean, I think anytime you're talking about an injury like that,' Stevens said. 'It's another piece of information that you have to ingest and figure out how that affects you moving forward for next year and into the future.' More Celtics content Read the original article on MassLive.

Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress
Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress

Business Wire

time2 days ago

  • Business Wire

Astria Therapeutics Announces Positive Initial Results from the ALPHA-SOLAR Long-Term Open-Label Trial of Navenibart in Hereditary Angioedema Patients at the European Academy of Allergy and Clinical Immunology Annual Congress

BOSTON--(BUSINESS WIRE)-- Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced positive initial results from the target enrollment group in the ongoing ALPHA-SOLAR long-term open-label trial evaluating navenibart (STAR-0215), a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (HAE) patients. These results demonstrated robust overall reduction in the monthly attack rate (92% mean and 97% median). These results further support navenibart's favorable safety and tolerability profile, and potential every three- (Q3M) and every six-month (Q6M) dosing regimens. 'We are thrilled to share positive initial results from the ALPHA-SOLAR long-term open-label trial,' said Christopher Morabito, M.D., Chief Medical Officer at Astria Therapeutics. 'Results are consistent with navenibart's best-in-class profile that we saw in the ALPHA-STAR Phase 1b/2 trial. With now 12 to 18 months on navenibart, these ALPHA-SOLAR results support navenibart's favorable profile and the potential to administer navenibart every 3 and every 6 months. The Phase 3 ALPHA-ORBIT trial is evaluating both every 3- and every 6-month regimens and is actively enrolling patients. Navenibart's profile and results that we have seen to date demonstrate the potential for navenibart to be the market-leading HAE therapy.' 'The navenibart results in patients to date support the potential for patients to have long-acting protection from their HAE attacks with very low treatment burden,' said Dr. William Yang, M.D., PRCPC, FAAAAI, Chair, Ottawa Allergy Research Corporation and Red Maple Trials Inc. 'We are excited for the Phase 3 ALPHA-ORBIT trial and believe that navenibart's profile with infrequent dosing could allow patients to spend less time thinking about their HAE, and more time living their lives.' ALPHA-SOLAR is a long-term open-label trial in adults with HAE Type 1 or 2 designed to assess long-term safety and efficacy of navenibart. All 16 target enrollment participants from the Phase 1b/2 ALPHA-STAR trial elected to enroll in ALPHA-SOLAR. ALPHA-STAR patients from Cohorts 1 and 2 enrolled in Arm A, and ALPHA-STAR patients from Cohort 3 enrolled in Arm B (described in the table below). Initial results from ALPHA-SOLAR 1: Comparisons to baseline from ALPHA-STAR. Navenibart demonstrated overall attack-freedom of 50% over six months, which is the longest period of follow-up for all 16 patients to date. All patients remain in the ALPHA-SOLAR trial. Navenibart was well-tolerated with no severe or serious treatment-emergent adverse events (TEAEs) and no discontinuations. One participant experienced two treatment-related, mild injection site reactions that resolved without treatment. There were no injection site reactions of pain. The safety profile of navenibart in patients with HAE was favorable through more than 17 months (median / mean) of cumulative follow-up since the initiation of navenibart in ALPHA-STAR. The results shared above are available in a poster presented at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Congress on June 13, 2025. The poster is accessible to conference attendees and also in the Scientific Presentations and Publications section of In February 2025, Astria initiated the pivotal Phase 3 ALPHA-ORBIT trial, which is evaluating navenibart administered Q3M and Q6M and currently enrolling patients. For more information, visit NCT06842823 or About Navenibart: Navenibart is a monoclonal antibody inhibitor of plasma kallikrein in development for the treatment of HAE. Our goal with navenibart is to provide rapid and sustained HAE attack prevention with a validated mechanism and trusted modality administered subcutaneously every 3 and 6 months. We aim to empower people living with HAE to live life without limitations from their disease. About Astria Therapeutics: Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. Our lead program, navenibart (STAR-0215), is a monoclonal antibody inhibitor of plasma kallikrein in clinical development for the treatment of hereditary angioedema. Our second program, STAR-0310, is a monoclonal antibody OX40 antagonist in preclinical development for the treatment of atopic dermatitis. Learn more about our company on our website, or follow us on Instagram @AstriaTx and on Facebook and LinkedIn. Forward Looking Statements: This press release contains forward-looking statements within the meaning of applicable securities laws and regulations including, but not limited to, statements regarding: our expectations regarding the potential significance of the results from the navenibart Phase 1b/2 ALPHA-STAR clinical trial and initial results from the ALPHA-SOLAR trial; the goals and objectives of the ALPHA-ORBIT trial; the potential therapeutic benefits of navenibart as a treatment for HAE; the potential attributes and profile of navenibart as a treatment for HAE, including its potential to be a life-changing, market leading preventative treatment for HAE, and our overall vision and goals for the navenibart program; and our corporate strategy and vision, including our mission is to bring life-changing therapies to patients and families affected by allergic and immunologic diseases. The use of words such as, but not limited to, 'anticipate,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'goals,' 'intend,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'should,' 'target,' 'will,' 'would,' or "vision," and similar words expressions are intended to identify forward-looking statements. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on Astria's current beliefs, expectations and assumptions regarding the future of its business, future plans and strategies, future financial performance, results of pre-clinical and clinical results of the Astria's product candidates and other future conditions. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including risks and uncertainties related to: changes in applicable laws or regulations; the possibility that we may be adversely affected by other economic, business, and/or competitive factors; risks inherent in pharmaceutical research and development, such as: adverse results in our drug discovery, preclinical and clinical development activities, the risk that the results of preclinical studies may not be replicated in clinical trials, that the preliminary, initial or interim results from clinical trials may not be indicative of the final results, that the results of early stage clinical trials, such as the results from the ALPHA-STAR Phase 1b/2 clinical trial, may not be replicated in later stage clinical trials, such as the planned Phase 3 development program, the risk that we may not be able to enroll sufficient patients in our clinical trials on a timely basis, and the risk that any of our clinical trials may not commence, continue or be completed on time, or at all; decisions made by, and feedback received from, the U.S. Food and Drug Administration and other regulatory authorities on our regulatory and clinical trial submissions and other feedback from potential clinical trial sites, including investigational review boards at such sites, and other review bodies with respect to navenibart, STAR-0310, and any other future development candidates; our ability to manufacture sufficient quantities of drug substance and drug product for navenibart, STAR-0310, and any other future product candidates on a cost-effective and timely basis, and to develop dosages and formulations for navenibart, STAR-0310, and any other future product candidates that are patient-friendly and competitive; our ability to develop biomarker and other assays, along with the testing protocols therefor; our ability to obtain, maintain and enforce intellectual property rights for navenibart, STAR-0310 and any other future product candidates; our potential dependence on collaboration partners; competition with respect to navenibart, STAR-0310, or any of our other future product candidates; the risk that survey results, modeling data and market research may not be accurate predictors of the commercial landscape for HAE, the ability of navenibart to compete in HAE and the anticipated position and attributes of navenibart in HAE based on clinical data to date, its preclinical profile, pharmacokinetic modeling, market research and other data; risks that any of our clinical trials of STAR-0310 may not commence, continue or be completed on time, or at all; risks that results of preclinical studies of STAR-0310 will not be replicated in clinical trials; our ability to manage our cash usage and the possibility of unexpected cash expenditures; our ability to obtain necessary financing to conduct our planned activities and to manage unplanned cash requirements; the risks and uncertainties related to our ability to recognize the benefits of any additional acquisitions, licenses or similar transactions; and general economic and market conditions; as well as the risks and uncertainties discussed in the 'Risk Factors' section of our Annual Report on Form 10-K for the period ended December 31, 2024 and in other filings that we may make with the Securities and Exchange Commission. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Astria may not actually achieve the forecasts or expectations disclosed in our forward-looking statements, and investors and potential investors should not place undue reliance on Astria's forward-looking statements. Neither Astria, nor its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing Astria's views as of any date subsequent to the date hereof.

Starton Therapeutics Announces Phase 2a Clinical Trial for Continuous Low-Dose Lenalidomide (STAR-LLD) in Multiple Myeloma Open for Enrollment
Starton Therapeutics Announces Phase 2a Clinical Trial for Continuous Low-Dose Lenalidomide (STAR-LLD) in Multiple Myeloma Open for Enrollment

Yahoo

time3 days ago

  • Yahoo

Starton Therapeutics Announces Phase 2a Clinical Trial for Continuous Low-Dose Lenalidomide (STAR-LLD) in Multiple Myeloma Open for Enrollment

Gabrail Cancer & Research Center activated and open to screen patients, with Nash Gabrail, MD as lead investigator Second site, Regional Medical Oncology Center, also activated Recent Phase 1b clinical study results concluded continuous low dose lenalidomide provides meaningful efficacy and improved tolerability with no grade >3 drug-related hematologic toxicity PARAMUS, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. ('Starton'), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technologies, announced today Gabrail Cancer Center (GCC) in Canton, Ohio is now activated and open for enrolling patients in its Phase 2a clinical trial evaluating their continuous low-dose lenalidomide, STAR-LLD, for the treatment of multiple myeloma (MM). Dr. Nash Gabrail, medical oncologist and founder of the Center, is the study's lead investigator. Regional Medical Oncology Center, located in Wilson, NC, has also opened as the trial's second active clinical site. 'We are excited to announce this major milestone in our mission to bring breakthrough therapies to patients. This marks the next phase of development for our lead candidate, STAR-LLD, and represents a significant step forward for the entire team," stated Pedro Lichtinger, Chairman and Chief Executive Officer of Starton Therapeutics. 'We expect this study to expand on what we observed in our prior Phase 1b study, that continuous low-dose lenalidomide provides meaningful efficacy and improved tolerability,' added Dr. Jamie Oliver, Starton's Chief Medical Officer. 'The expanded cohort and dose escalation will help us determine the most effective dose, with the goal of maintaining acceptable safety and tolerability.' Starton, which recently presented the results of the Phase 1b portion of the study at the 2025 American Association for Cancer Research, will assess the safety and tolerability of low-dose lenalidomide in heavily treated MM patients. Continuous SC infusion (STAR-LLD) in combination with dexamethasone and a protease inhibitor (PI) will be compared to oral lenalidomide (Revlimid®) in combination with dexamethasone and a PI. The study will include at least 24 patients randomized to STAR-LLD and oral lenalidomide (Revlimid®). Up to 45 additional patients may be enrolled to identify the optimal dose for a future registrational study (based on ORR vs dose vs Grade 3-4 toxicity). Starton anticipates opening approximately 10 clinical sites. About STAR-LLD STAR-LLD is a continuous delivery lenalidomide (LLD) in development to expand and replace the standard-of-care for the most common blood cancers, multiple myeloma (MM), and chronic lymphocytic leukemia (CLL). A preclinical proof-of-concept study for subcutaneous STAR-LLD demonstrated that MM tumors caused by human myeloma cells grew 25-fold if untreated, five-fold when treated with daily lenalidomide, and shrank by 80% with STAR-LLD over a single 28-day cycle. The study also showed a 100% overall response rate (ORR) using continuous delivery LLD and 20% of animals in this cohort were tumor-free after 100 days, compared to a 0% ORR in animals treated with a 70% higher dose of lenalidomide given in single daily doses. In addition, a Phase 1b clinical study of six relapsed/refractory MM patients resulted in all patients that received STAR-LLD achieving an objective response (1 CR and 5 PRs); no patients experienced drug-related anemia, neutropenia, leukopenia, or thrombocytopenia greater than grade 2 in up to 12 cycles of therapy. The study concluded that continuous delivery of low dose lenalidomide (STAR-LLD) provides meaningful efficacy and improved tolerability with no grade > 2 drug-related hematologic toxicity. About Starton Therapeutics Starton Therapeutics is a clinical-stage biotechnology platform company focused on transforming standard-of-care therapies with proprietary continuous delivery technology, so people with cancer live better, for longer. Starton's proprietary technology is intended to increase the efficacy of approved drugs, make them more tolerable, and expand their potential use. To learn more, visit Forward Looking Statements All statements other than statements of historical facts included in this press release, including, without limitation, statements regarding our plans and objectives for future operations and expectations about current and future clinical trials, constitute 'forward-looking statements.' Forward-looking statements are subject to numerous conditions and known and unknown risks and uncertainties that could cause our actual results or events to differ materially from those included within the forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, and except as required by law, Starton undertakes no obligation to disclose any revision to these forward-looking statements whether as a result of new information, future events, or otherwise. Investor Relations Contact Alex StarrManaging Director LifeSci Advisors astarr@ in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store